Share chart Annovis Bio, Inc.
Extended chart
Simple chart
About Annovis Bio, Inc.
Annovis Bio, Inc., компания, занимающаяся разработкой лекарственных препаратов клинической стадии, разрабатывает препараты для лечения нейродегенерации. Ведущим препаратом компании является Бунтанетап, препарат для перорального применения, который прошел клинические испытания фазы 2а для лечения болезни Альцгеймера (БА) и болезни Паркинсона, а также проходит клинические испытания для лечения болезни Альцгеймера при синдроме Дауна и других хронических нейродегенеративных заболеваниях. . more details| IPO date | 2010-02-12 |
|---|---|
| ISIN | US03615A1088 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.annovisbio.com |
| Цена ао | 1.85 |
| Change price per day: | 0% (1.85) |
|---|---|
| Change price per week: | +2.78% (1.8) |
| Change price per month: | +2.78% (1.8) |
| Change price per 3 month: | -64.15% (5.16) |
| Change price per half year: | -77.16% (8.1) |
| Change price per year: | -84.62% (12.03) |
| Change price per 3 year: | -87.07% (14.31) |
| Change price per 5 year: | -63.65% (5.09) |
| Change price per year to date: | -63.07% (5.01) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Vanguard Group Inc | 337354 | 3.06 |
| Adage Capital Partners GP L.L.C. | 285347 | 2.59 |
| Blackrock Inc. | 95984 | 0.87 |
| Geode Capital Management, LLC | 68776 | 0.62 |
| Wescott Financial Advisory Group, LLC | 41607 | 0.38 |
| Sterling Investment Advisors, Ltd. | 34374 | 0.31 |
| Redmond Asset Management, LLC | 34080 | 0.31 |
| Marshall Wace LLP | 32582 | 0.3 |
| Modera Wealth Management, LLC | 30513 | 0.28 |
| Northern Trust Corporation | 29048 | 0.26 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.01781 | 17.09 | 1.54048 |
| 0.02 | 17.09 | 1.54 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, CEO, President, Interim Principal Financial Officer & Executive Director | 965.6k | 1951 (74 years) |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development | N/A | |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations | N/A | |
| Ms. Melissa Gaines | Senior Vice President of Clinical Operations | N/A | |
| Mr. Mark K. White | Chief Business Officer & Director | 1956 (69 years) | |
| Mr. Blake Jensen | Head of Quality | ||
| Ms. Hilda Maibach | Senior Vice President of Statistics |
Address: United States, Berwyn. PA, 1055 Westlakes Drive - open in Google maps, open in Yandex maps
Website: https://www.annovisbio.com
Website: https://www.annovisbio.com
